Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Latest Biotechnology and Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings, Inc. Stock News

As of October 9, 2026, Halozyme Therapeutics, Inc. had a $12.5 billion market capitalization, compared to the Biotechnology median of $242.6 million. Halozyme Therapeutics, Inc.’s stock is up 64.1% in 2026, up 0.5% in the previous five trading days and up 69.36% in the past year.

Currently, Halozyme Therapeutics, Inc.’s price-earnings ratio is 32.6. Halozyme Therapeutics, Inc.’s trailing 12-month revenue is $1.7 billion with a 24.9% net profit margin. Year-over-year quarterly sales growth most recently was 47.7%. Analysts expect adjusted earnings to reach $8.714 per share for the current fiscal year. Halozyme Therapeutics, Inc. does not currently pay a dividend.

As of October 9, 2026, Maravai LifeSciences Holdings, Inc. had a $1.1 billion market cap, putting it in the 47th percentile of all stocks. Maravai LifeSciences Holdings, Inc.’s stock is up 128.9% in 2026, down 5.8% in the previous five trading days and up 123.42% in the past year.

Currently, Maravai LifeSciences Holdings, Inc. does not have a price-earnings ratio. Maravai LifeSciences Holdings, Inc.’s trailing 12-month revenue is $208.8 million with a -37.1% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $-0.107 per share for the current fiscal year. Maravai LifeSciences Holdings, Inc. does not currently pay a dividend.

How We Compare Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Halozyme Therapeutics, Inc.	HALO	D
Maravai LifeSciences Holdings, Inc.	MRVI	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Halozyme Therapeutics, Inc. has a Value Score of 29, which is Expensive. Maravai LifeSciences Holdings, Inc. has a Value Score of 13, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to value.

Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc.’s Momentum Grades

Company	Ticker	Momentum
Halozyme Therapeutics, Inc.	HALO	A
Maravai LifeSciences Holdings, Inc.	MRVI	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Halozyme Therapeutics, Inc. has a Momentum Score of 92, which is Very Strong. Maravai LifeSciences Holdings, Inc. has a Momentum Score of 95, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Halozyme Therapeutics, Inc.	HALO	B
Maravai LifeSciences Holdings, Inc.	MRVI	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Halozyme Therapeutics, Inc. has a Earnings Estimate Score of 76, which is Positive. Maravai LifeSciences Holdings, Inc. has a Earnings Estimate Score of 77, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc. have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings or Inc. is a better fit.

Other Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc. Grades

In addition to Value, Momentum and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings or Inc. Stock?

Overall, Halozyme Therapeutics, Inc. stock has a Value Score of 29, Momentum Score of 92 and Estimate Revisions Score of 76.

Maravai LifeSciences Holdings, Inc. stock has a Value Score of 13, Momentum Score of 95 and Estimate Revisions Score of 77.

Comparing Halozyme Therapeutics, Inc., Maravai LifeSciences Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.